- a.Whether pharmaceutical price regulation is effective in reducing expenditures is inconclusive, with both positive and negative results documented in previous research.
- b.This paper contributes by providing evidence from Canada. It also contributes to understanding the policy mechanisms, with a focus on the demand-side incentives and the role of health insurance, which were rarely discussed in previous research.
- c.The mechanisms analysis suggests that the ability of price controls rests on the interaction with demand-side regulations and incentives. The success in cost containment in Canada can provide some insights to other countries with similar needs and priority.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Publication stageIn Press Accepted Manuscript
A summary of the article: The Canadian generic policy has significantly reduced drug expenditure per capita while it has little impact on individual utilization.
AUTHOR DISCLOSURES [VIH-2022-0710]
Concept and design: Li
Acquisition of data: Li
Analysis and interpretation of data: Li
Drafting of the manuscript: Li
Critical revision of the paper for important intellectual content: Li
Statistical analysis: Li
Provision of study materials or patients: Li
Conflict of Interest Disclosures: The author reported no conflicts of interest.
Funding/Support: The author received no financial support for this research.
Role of the Funder/Sponsor: Not Applicable.
I would like to thank the editor and the anonymous reviewers for their valuable comments, which helped improve the quality and presentation of the work. I deeply thank Dr. Erin Strumpf and Dr. Laura Lasio for their suggestions and feedback.